^
    Back
    Association details:
    Biomarker:PIM1 mutation
    Cancer:Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Adv Clin Exp Med
    Title:

    The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants

    Published date:
    03/07/2023
    Excerpt:
    We aimed to explore the efficacy of ibrutinib in treating r/r CNSL patients, and whether genomic variants impact treatment outcomes….The PCNSL patients harboring gene mutations in PIM1, MYD88 and CD79B, and the proximal BCR and nuclear factor kappa B (NF-κB) pathways responded to ibrutinib.
    DOI:
    10.17219/acem/159288